Bergner Medical Consulting

The global immuno-oncology (IO) market is at a critical inflection point, with the era of single-agent PD-1/PD-L1 inhibitors giving way to multi-functional biologics. This market for bispecific antibodies (BsAbs) is projected to experience explosive growth, conservatively reaching between $15.1 bill ...

The Antibody-Drug Conjugate (ADC) market is undergoing a profound transformation, evolving into a cornerstone of modern oncology. This explosive growth is projected to expand the market from approximately $10–$13.5 billion in 2023 to a valuation as high as $50 billion by 2030, driven by a 14-15% CAG ...